Results.
In multivariable analysis, low copy number of CNR1 (including FCGR3B; OR 2.04; 95% CI: 1.29 -3.23), FCGR2A-131RR (OR 2.00; 95% CI: 1.33 -2.99), and the 2B.4 haplotype of FCGR2B (OR 1.59; 95% CI: 1.13 -2.24), but not FCGR2C-ORF, were significantly (all p<0.01) and independently associated with susceptibility to SLE. The 2B.4 haplotype was negatively associated with LN and led to surface expression of FcγRIIb on neutrophils and monocytes.
Conclusion.
This study is the first to investigate the most relevant and functional SNPs and CNVs of FcγRII and FcγRIII polymorphisms in one study population, enabling the determination of the individual contribution of each polymorphism in multivariable analysis. Three polymorphisms were shown to be independently associated with susceptibility to SLE. The novel findings of a negative association of the 2B.4 haplotype with LN, and increased expression of FcγRIIb on neutrophils and monocytes as a result of this 2B.4 haplotype warrant future research in the role of these cells and FcγRs in the pathogenesis of SLE and LN. 51 
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FcγR polymorphisms differentially influence SLE | introduction Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by the formation of autoantibodies, deposition of immune complexes and inflammation, and can affect virtually every organ system in the body. Aetiologically, a multifactorial model is presumed, including genetic, hormonal and environmental factors, in which defective clearance and degradation of apoptotic cells is thought to have a pivotal role in developing SLE 1, 2 .
The receptors for the Fc portion of IgG (Fc-gamma Receptors, FcγRs) play an important role in the clearance of immune complexes and presentation of the complexed antigen, and provide pro-or anti-inflammatory regulation of immune cell responses 3 . There are three families of FcγRs of which FcγRI is a high-affinity receptor and FcγRII and FcγRIII are low-affinity receptors 4 .
Within these families different subclasses exist. FcγRs trigger activating signalling pathways, except FcγRIIb, which triggers inhibitory signalling pathways. FcγRIIIb is a distinct receptor expressed on neutrophils that is not known to associate with signalling molecules. Although it may activate cells in some cases, it may also function as a decoy receptor, helping to clear immune complexes 5, 6 . Failure of FcγR-mediated clearance of immune complexes and control of inflammatory responses are thought to be predisposing factors for the development of SLE 7 .
The relationship between SLE and FcγRs has been extensively studied 8 . The FCGR2/3 locus on chromosome 1q23.3 that encodes the low-affinity FcγRs is subject to both single nucleotide polymorphisms (SNPs) and copy number variation (CNV) (Fig.1 ) 9 . Indeed, several of these polymorphisms lead to an altered function of FcγRs [10] [11] [12] [13] . Meta-analyses have shown an increased risk for the development of SLE for these polymorphisms, with considerable differences between ethnic groups [14] [15] [16] [17] [18] [19] [20] . However, these meta-analyses only studied the effect of a single polymorphism and did not take linkage disequilibrium (LD) into account. Furthermore, studies on the relationship between two specific polymorphisms and susceptibility to and clinical manifestations of SLE are very limited or even absent. The first, FCGR2C-open reading frame (ORF), is the result of a SNP in exon 3 on FCGR2C that leads to an ORF, instead of the more common stop codon (FCGR2C-Stop) 21, 22 . If an ORF is present, then FcγRIIc is expressed on natural killer cells and is able to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and a rise in intracellular Ca 2+ (23, 24) . FCGR2C-ORF has not been previously described in relation to SLE. The other, a SNP in the promoter region of FcγRIIb, also known as 2B.4, was found to be more frequently present in SLE patients compared to healthy controls, although the functional consequences of this SNP are not completely clear 25, 26 .
Studies on associations between FcγR polymorphisms and specific clinical manifestations of SLE have mainly focused on lupus nephritis (LN), defined according to ACR criteria (proteinuria and/or cell casts) or biopsy-proven. Associations with LN were found for <2 copies of FCGR3B and the FCGR3A-158F allele 18, 27, 28 , but not for other polymorphisms 14, 19, 20 . Only a limited number of studies investigated the relationship between FcγR polymorphisms and other clinical SLE manifestations. These studies were performed in patient groups of different ethnic backgrounds and reported various associations without a distinct direction [29] [30] [31] .
The aim of the present study is to determine associations between several known and one novel (FCGR2C-ORF) genetic polymorphisms and susceptibility to SLE in Caucasian patients. Secondly, to investigate the relationship between specific polymorphisms and renal disease in SLE.
materials and Patients

Subjects
DNA was available from 266 Dutch Caucasian SLE patients and 919 healthy Caucasian controls (199 from the Netherlands, 156 from Australia, 478 from Austria, 86 from the UK) who were randomly selected. SLE patients were recruited from two longitudinal SLE cohorts from VU University Medical Center (VUmc) (n=98) and University Medical Center Groningen (UMCG) (n=86), and from the first and second Dutch Lupus Nephritis Study (n=82) 32 . In both Dutch Lu- 
Multiplex Ligation-dependent Probe Amplification
Multiplex Ligation-dependent Probe Amplification (MLPA) was performed as described extensively by Breunis et al. 23 . In short, MLPA probes were designed specifically for the FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B genes on multiple sites in the genes. In this way, CNV regions for FCGR2C, FCGR3A and FCGR3B could be defined (Fig.1 Probes were also included for the splice site mutation at the border of exon7-intron7 in FCGR2C (rs76277413 c.798 +1 A>G), to distinguish the non-expressed 'nonclassical' FCGR2C-ORF variant from the 'classical' FCGR2C-ORF that is typically expressed on natural killer (NK) cells, monocytes and neutrophils 22 . Because the nonclassical FCGR2C-ORF variant is not expressed 22 , it was grouped with FCGR2C-Stop in all statistical analyses. The assay also contained non-specific probes for the promoter regions of FCGR2B and FCGR2C; FCGR2B/C -386C>G (rs143796418 in FCGR2B, rs149754834 in FCGR2C) and FCGR2B/C -120A>T (rs780467580 in FCGR2B, rs34701572 in FCGR2C). These promoter polymorphisms make up the promoter haplotypes 2B.1, 2B.2 and 2B.4 as described by Su et al. 35 . Haplotype 2B.1 consists of a G at position -386 and a T at position -120 (nucleotide positions relative to start codon of FCGR2B or FCGR2C), haplotype 2B.2 consists of -386C and -120T, haplotype 2B.4 consists of -386C and -120A. Exact location of these promoter polymorphisms was determined with a gene-specific long-range PCR for FCGR2B and FCGR2C as described previously 23 . Since -120A
only occurred in the promoter of FCGR2B (Table S1 ), promoter haplotypes were constructed from MLPA data as follows: any C at -386 accompanied by an A at -120 was designated as a 2B.4, and was allocated to FCGR2B. For all seven individuals with 2B.4 haplotypes in FCGR2B studied for expression analysis, this was confirmed with the gene-specific long-range PCR for FCGR2B (Table S1 and data not shown).
Flow cytometry
Whole blood leukocytes were isolated from heparin blood by lysis of red blood cells with an isotonic ammonium chloride buffer. 
Statistical analysis
To determine susceptibility to SLE, the allele frequencies and copy number of copy number regions (CNRs) between SLE patients and healthy controls were compared using Fisher's exact test and logistic regression. Odds ratios (ORs), 95% confidence intervals (CI) and P-values were calculated. To determine which factors were independently associated with an increased susceptibility to SLE, all polymorphisms with a P <0.1 in the single regression model were put into a multiple logistic regression model. 
results
We determined the CNVs and SNPs of the low-affinity FcγR genes FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B genes with MLPA in 266 Caucasian SLE patients and 919 healthy controls. Allele frequencies of healthy controls between countries were very similar and no statistical differences were observed (p > 0.05) (data not shown). Demographic and cumulative clinical features of the SLE patients are shown in Table S2 . In the 186 patients of the VUmc and UMCG lupus cohorts, nephrological manifestations (i.e. presence of proteinuria > 0.5g/24 hours and/ or cell casts) were observed in 71 (38.6%) patients, of which 49 (26.6%) were biopsy proven. All 82 patients from the Dutch Lupus Nephritis Study had a history of nephrological manifestations and biopsy-proven LN. Table 1 shows the frequencies of tested CNVs and SNPs in SLE patients and healthy controls. In all patients and controls, CNV always occurred as a combination of FCGR2C with either FCGR3A or FCGR3B, in three distinct CNV regions (CNRs) as previously defined (Fig.1) 7 . The CNRs were analyzed as such for susceptibility to SLE and this revealed a significant association with low copy number of CNR1 (FCGR2C and FCGR3B) ( Table 2 ). Copy number changes in CNR2 or CNR3 were not significantly associated with susceptibility to SLE. For the SNPs, increased susceptibility to SLE was found for FCGR2A-131R and a trend for the 2B.4 haplotype of FCGR2B (Table 1) .
Susceptibility to SLE
FCGR2A-27W, FCGR3A-158V, FCGR2C-ORF, FCGR3B-NA1, FCGR3B-SH
and FCGR2B-232I were not associated with susceptibility to SLE ( Table 1) .
In a multivariable regression analysis, FCGR2A-131R, CNR1 and the 2B.4 haplotype were all independently and significantly associated with an increased susceptibility to SLE ( Table 2) .
Effect of FCGR3B CNV and the -386C/G and -120A/T SNPs in the promoter of FCGR2B on expression levels
Two of the three significantly associated variants conceivably have an impact on the expression levels of FcγRs. In order to test this relationship, the expression levels of different FcγRs on leukocytes were determined in a large group (n=135) of our Dutch Caucasian healthy controls, FcγR polymorphisms differentially influence SLE | using flow cytometry. Hereby, the strong correlation of FCGR3B copy number with expression of FcγRIIIb on neutrophils was confirmed (Fig.2) , indicating that CNV of FCGR3B results in a clear gene-dosage effect. When determining the effect of the promoter haplotype 2B.4 ( Fig.  3a) on expression levels of FcγRIIb it is important to consider that monoclonal antibodies that recognize the extracellular domain of FcγRIIb, will also recognize FcγRIIc. This is due to the fact that the extracellular part of these receptors is identical. Individuals with an FCGR2C-ORF will express FcγRIIc on NK cells, neutrophils and monocytes 22 , and possibly B cells 37 . The analysis of expressions levels of FcγRIIb should therefore be performed in FCGR2C-stop donors only. Five healthy FCGR2C-stop donors heterozygous for 2B.4 and two homozygous for 2B.4 were tested in an expression analysis. This revealed that the 2B.4 haplotype causes expression of FcγRIIb on neutrophils in the steady state, whereas in individuals with the 2B.1 haplotype, its expression is virtually absent (Fig.3b) . A similar effect was observed in monocytes (Fig.3c ), but on B cells, which express high levels of FcγRIIb, no difference between the different promoter haplotypes was observed (Fig.1f) . The 2B.4 haplotype did not cause expression of FcγRIIb on T cells or NK cells (Fig.1d,e ).
Susceptibility to LN
We then tested within the patient cohort for associations of FCGR2/3 polymorphisms with susceptibility to renal disease in SLE. This revealed that the presence of the FCGR2B promoter haplotype 2B.4 was statically significant and negatively associated with a clinical history of ne- phrological manifestations or biopsy-proven LN (Table 3) . Only two patients were homozygous for the 2B.4 haplotype and neither had a history of nephrological manifestations or biopsyproven LN. Other SNPs and CNVs were not significantly associated with renal manifestations or SLE. Out of 131 patients with biopsy-proven LN, 119 (90.8%) had a predominantly class III or IV LN, 9 (6.9%) had class V LN and 2 (1.5%) had class II LN. One patient had a biopsy-proven LN of which the class could not be retrieved by chart review. We did not observe any significant differences between the tested allele polymorphisms and classes III and IV LN compared to the other LN classes (data not shown). Finally, ORs and CIs of disease manifestations other than renal were calculated for the different polymorphisms (Table S3 ). In the presence of many clinical manifestations, a relatively small study population and multiple testing, no clear associations were found. 
discussion
The main findings of our study are an independent and significant association with susceptibility to SLE of FCGR2A-131R, copy number of CNR1 (including FCGR3B) and the 2B.4 haplotype in the promoter of FCGR2B, which encodes the inhibitory FcγRIIb. Furthermore, a negative association between the 2B.4 haplotype of FcγRIIb and renal disease was shown. Thirdly, and for the first time, FCGR2C-ORF in SLE was investigated and an association with increased susceptibility to SLE was not found.
The strength of the present study is that it is the first to investigate the most relevant and functional SNPs and CNVs of FcγRII and FcγRIII polymorphisms in one and the same study population, enabling the determination of the individual contribution of each polymorphism in multivariable analysis. This analysis has not been done before as extensively as in the current cohort study. Previous studies and meta-analyses focused on a single SNP or CNV in relationship to SLE and/or LN susceptibility. Furthermore, detailed data of the SLE patients were available, including the results of the gold standard for LN, which is renal biopsy.
Regarding susceptibility to SLE with FCGR2A-131R, two meta-analyses also demonstrated FCGR2A-131R to be a susceptible genotype in patients of European descent 16, 17 . In addition, a meta-analysis showed low copy number of FCGR3B to be a susceptibility genotype for SLE in a meta-analysis 38 . However, our data now show that CNV of FCGR3B occurs solely as a combined deletion of different genes, collectively termed CNR1, and therefore, the interpretation of a low copy number of FCGR3B may not be as straightforward as it seems. Deletion of CNR1 in theory has four effects that could contribute to SLE susceptibility, as it contains three genes (FCGR2C, HSPA7 and FCGR3B) with CNV, and additionally leads to the ectopic expression of FcγRIIb on NK cells 22 . However, CNV of FCGR2C in itself cannot account for susceptibility to SLE, being in most cases a pseudogene (and only the number of copies of the FCGR2C-ORF variant is associated with functional differences). Similarly, HSPA7 is a non-expressed pseudogene. On the other hand, individuals with a deletion of CNR1 all had ectopic expression of FcγRIIb on NK cells, confirming our earlier finding in a larger group 22 . Indeed, the ectopic expression of FcγRIIb on NK cells was recently suggested as a potential explanation for the increased susceptibility to SLE 39 , although not supported by any experimental evidence. The gene dosage effect of copy number of FCGR3B on FcγRIIIb expression therefore seems to be the more prominent and logical explanation for the susceptibility to SLE, as it may lead to impaired clearance of immune complexes from the circulation 5, 6 . Finally, the third risk factor identified in our susceptibility study was the promoter haplotype 2B.4, which confirms the findings of two earlier studies 25, 26 .
The effects of this promoter haplotype that have been reported thus far are contradictory. One group showed an increase of FcγRIIb on B cells as well as monocytes and neutrophils when 2B.4 was present 13, 25 , whereas another study demonstrated an opposite effect, arguing that the 2B.4
haplotype resulted in a decrease of FcγRIIb on B cells 26 . A potential bias that may have resulted in these discordant findings is expression of FcγRIIc, which is highly homologous to FcγRIIb. Another novel finding of the present study is the negative association of the FCGR2B promoter haplotype 2B.4 with LN (in both clinically and biopsy-proven LN). Whereas the 2B.4 promoter in SLE contributes to susceptibility to SLE, it may also protect against the development of LN. Besides a negative association of the 2B.4 haplotype with LN, we also observed a negative association with specific auto-antibodies (immunological manifestations according to ACR criteria; Table S3 ), including anti-dsDNA. Previous studies have shown a clear association between the presence of anti-dsDNA and LN 40 . Recent studies have shown neutrophil extracellular traps (NETs) to be of pathophysiological importance in SLE 41 . NETs are able to trap invading microbes and subsequently eliminate them by NETosis. NETs contain DNA and histones, which could be a potential source for autoantigens. Furthermore, degradation of NETs seems to be impaired in SLE and is associated with increased titres of anti-dsDNA and LN 42, 43 . A potential hypothesis for our negative association between 2B.4 haplotype and LN could be that increased FcγRIIb expression on neutrophils increases the threshold for NET formation, thereby decreasing the levels of anti-dsDNA and the chance for development of LN. Together with the FCGR3B genedosage effect and low FcγRIIIb expression on neutrophils, this inflammatory cell type may well contribute to the pathogenesis of SLE. Other FcγR polymorphisms were not associated with LN in the present study. Regarding FCGR3A-158, one meta-analysis reported an association with LN for the FCGR3A-158FF genotype 18 , which was not found in a more recent meta-analysis 14 . Two earlier studies reported an association between low copy number (<2) of FCGR3B and LN compared to no renal involvement in 107 and 204 SLE patients, respectively 27, 28 . In a larger study amongst 536 SLE patients of whom 161 had LN, this association of FCGR3B with LN was not observed 20 .
A potential limitation of our study is that the MLPA probes for the 2B.4 promoter haplotype cannot distinguish between FCGR2B and FCGR2C. To solve this problem, we determined the exact location of the 2B.4 promoter haplotype in a large group of individuals and showed that the 2B.4 promoter exclusively occurred in FCGR2B, confirming that our approach of allocating this haplotype to FCGR2B is correct.
In conclusion, our study demonstrates the pertinent and independent role of low-affinity FcγR polymorphisms in the susceptibility to SLE and one of its most serious clinical manifestations, LN. The polymorphic variants associated with SLE lead to less avid binding of pro-inflammatory suPPlementary data -386 -120 2b.1 2b.2 2b.4 -386 -120 2b.1 2b.2 2b.4 FCGR2C cnV < 2 -386 -120 2b.1 2b.2 2b.4 -386 -120 2b.1 2b.2 The 2B.4 haplotype is attributable to FCGR2B. MLPA reliably determines the amount and nature of promoter haplotypes 2B.1, 2B.2 and 2B.4 in FCGR2B and FCGR2C, but does not provide specific information about their location in either FCGR2B or FCGR2C. In the majority of cases, only the 2B.1 (wild type) haplotype is detected, and therefore, allocation is straightforward in these cases. However, when other haplotypes are also present in an individual, allocation is not straightforward. Therefore, we further analyzed a selection of 36 healthy individuals from the control group that had ≥1 non-wild type promoter haplotype as determined by MLPA by gene specific long-range PCR followed by Sanger sequencing with a nested primer to determine the location of the promoter haplotypes. Donor selection was aimed at including at least four individuals with decreased and increased copy number, but otherwise, the selection was random. Sanger sequencing results for FCGR2B are shown on the left, results for FCGR2C are shown on the right. The -386 and -120 nucleotide (prior to the start codon) SNPs that determine the haplotypes are shown together with the resulting haplotypes. The results were always concordant with the results of the MLPA. The analysis revealed that 2B.4 haplotypes were always located in FCGR2B, as no single FCGR2C gene carried this 2B.4 haplotype. Together with previous reports that link the 2B.4 haplotype to FCGR2B 1, 2 , these results show that 2B.4 can be allocated to FCGR2B, also if only MLPA is performed. The 2B.2 haplotype was almost exclusively found in FCGR2C, but also occurred in FCGR2B in 3 out of 4 individuals with a deletion of FCGR2C (all these cases had a deletion of CNR1). Therefore, allocation of 2B.2 haplotypes detected by MLPA is more difficult in cases with a decreased copy number of FCGR2C, but it can be allocated to FCGR2C in cases with normal copy number. Furthermore, the 2B.2 haplotype in FCGR2C was very strongly linked to the FCGR2C-ORF haplotype, as shown in the last column. 
